Failure to identify modifiers of NEBULIN-related nemaline myopathy in two pre-clinical models of the disease
Publisher
COMPANY BIOLOGISTS LTDCitation
Qiu, B., Ruston, J., Granzier, H., Justice, M. J., & Dowling, J. J. (2019). Failure to identify modifiers of NEBULIN-related nemaline myopathy in two pre-clinical models of the disease. Biology Open, 8(9), bio044867.Journal
BIOLOGY OPENRights
Copyright © 2019. Published by The Company of Biologists Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Nemaline myopathy is a rare neuromuscular disorder that affects 1 in 50,000 live births, with prevalence as high as 1 in 20,000 in certain populations. 13 genes have been linked to nemaline myopathy (NM), all of which are associated with the thin filament of the muscle sarcomere. Of the 13 associated genes, mutations in NEBULIN (NEB) accounts for up to 50% of all cases. Currently, the disease is incompletely understood and there are no available therapeutics for patients. To address this urgent need for effective treatments for patients affected by NM, we conducted a large scale chemical screen in a zebrafish model of NEB-related NM and an N-ethyl-N-nitrosourea (ENU)-based genetic screen in a mouse model of NEB exon 55 deletion, the most common NEB mutation in NM patients. Neither screen was able to identify a candidate for therapy development, highlighting the need to transition from conventional chemical therapeutics to gene-based therapies for the treatment of NM.Note
Open access journalISSN
2046-6390PubMed ID
31530540Version
Final published versionSponsors
United States Department of Health & Human Services - National Institutes of Health (NIH) - USA [R01AR053897]; HSBC Bank Canada catalyst grant from the Hospital for Sick Children; operating grant from A Foundation Building Strengthae974a485f413a2113503eed53cd6c53
10.1242/bio.044867
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2019. Published by The Company of Biologists Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0).
Related articles
- Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy.
- Authors: Ottenheijm CA, Buck D, de Winter JM, Ferrara C, Piroddi N, Tesi C, Jasper JR, Malik FI, Meng H, Stienen GJ, Beggs AH, Labeit S, Poggesi C, Lawlor MW, Granzier H
- Issue date: 2013 Jun
- Neb: a zebrafish model of nemaline myopathy due to nebulin mutation.
- Authors: Telfer WR, Nelson DD, Waugh T, Brooks SV, Dowling JJ
- Issue date: 2012 May
- Thin filament length dysregulation contributes to muscle weakness in nemaline myopathy patients with nebulin deficiency.
- Authors: Ottenheijm CA, Witt CC, Stienen GJ, Labeit S, Beggs AH, Granzier H
- Issue date: 2009 Jul 1
- NRAP reduction rescues sarcomere defects in nebulin-related nemaline myopathy.
- Authors: Casey JG, Kim ES, Joseph R, Li F, Granzier H, Gupta VA
- Issue date: 2023 May 5
- Comprehensive phenotypic characterization of an allelic series of zebrafish models of NEB-related nemaline myopathy.
- Authors: Fabian L, Karimi E, Farman GP, Gohlke J, Ottenheijm CAC, Granzier HL, Dowling JJ
- Issue date: 2024 Mar 17